MedPath

Cariprazine

Generic Name
Cariprazine
Brand Names
Vraylar, Reagila
Drug Type
Small Molecule
Chemical Formula
C21H32Cl2N4O
CAS Number
839712-12-8
Unique Ingredient Identifier
F6RJL8B278
Background

Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.

Indication

Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Associated Conditions
Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
Clinical Trials
Related News

2025 Pharmaceutical Pipeline: Major Patent Expirations Set to Transform Drug Market with Generics and Biosimilars

• The US pharmaceutical market is poised for significant change in 2025 as several blockbuster drugs including Xarelto, Entresto, and Stelara face patent expirations, opening the door to generic and biosimilar competition. • Multiple biosimilars for ustekinumab (Stelara) are entering the market in 2025, with Wezlana already launched in January as the first interchangeable biosimilar, while other major drugs like ticagrelor and denosumab will also face competition. • The pharmaceutical pipeline continues to expand with innovative therapies for cancer and neurological disorders, alongside the Medicare Drug Price Negotiation program which will further impact pricing dynamics for high-cost medications.

Bipolar Depression Market Set to Grow Through 2034 with New Therapies in Pipeline

• The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions. • Several pharmaceutical companies including NeuroRx, COMPASS Pathways, and Intra-Cellular Therapies are advancing novel treatments, with Johnson & Johnson's recent $14.6 billion acquisition of Intra-Cellular Therapies highlighting industry confidence in the sector. • Among current therapies, CAPLYTA (lumateperone) is expected to achieve the highest market share by 2034, while emerging treatments like NRX-100/101 and COMP 360 (psilocybin) show promise for addressing unmet needs in bipolar depression management.

Sana Biotechnology Achieves Breakthrough in Type 1 Diabetes Treatment Without Immunosuppression

Sana Biotechnology has reported promising early trial results for type 1 diabetes treatment using allogeneic pancreatic islet cell transplantation without the need for immunosuppression. This groundbreaking development represents the first human evidence of successfully overcoming both allogeneic and autoimmune rejection in type 1 diabetes treatment.

Medicare to Negotiate Single Price for Novo's Semaglutide Products Including Ozempic and Wegovy

• Medicare has selected semaglutide as one of 15 drugs for its second round of price negotiations, treating all formulations including Ozempic, Wegovy, and Rybelsus as a single product. • The negotiations will establish a unified "maximum fair price" for all semaglutide products, impacting Novo Nordisk's medications that currently list at $998-$1,349 per month. • CMS's approach focuses on the drug's active moiety rather than individual brand names, aiming to prevent "product hopping" and ensure consistent pricing across different formulations.

AbbVie's Emraclidine Fails in Phase 2 Schizophrenia Trials, $9B Acquisition Questioned

• AbbVie's emraclidine, a key asset from the Cerevel Therapeutics acquisition, failed to outperform placebo in two Phase 2 trials for schizophrenia, raising concerns about the $9 billion investment. • The trials, involving approximately 750 participants, assessed emraclidine's efficacy across multiple doses using a standard schizophrenia symptom scale over six weeks. • The failure potentially benefits Bristol Myers Squibb's Cobenfy, removing a significant competitive threat in the schizophrenia treatment landscape, according to analysts. • Despite the setback, AbbVie reaffirms its commitment to neuroscience, highlighting its recent $1.4 billion investment in an Alzheimer's treatment and the broader pipeline acquired from Cerevel.

AbbVie's Emraclidine Fails to Meet Primary Endpoint in Phase 2 Schizophrenia Trials

• AbbVie's emraclidine, an oral monotherapy for schizophrenia, did not achieve statistically significant improvement in two Phase 2 trials, causing AbbVie shares to decline. • Despite the setback, AbbVie will continue analyzing the data to determine the next steps for emraclidine's development in psychiatric disorders. • AbbVie's focus remains on its pipeline of innovative therapies, particularly after acquiring Cerevel Therapeutics for $8.7 billion to expand its offerings in schizophrenia treatment. • Bristol-Myers Squibb's schizophrenia drug, Cobenfy (KarXT), recently gained FDA approval, following their acquisition of Karuna Therapeutics for $14 billion.

Intra-Cellular Therapies Seeks FDA Approval for Caplyta in Major Depressive Disorder

• Intra-Cellular Therapies has submitted a supplemental New Drug Application to the FDA for Caplyta (lumateperone) as an adjunct treatment for Major Depressive Disorder (MDD). • Caplyta, already approved for schizophrenia and bipolar disorder, demonstrated significant improvement in depression symptoms in Phase 3 trials when added to existing antidepressants. • The application is supported by positive results from double-blind, placebo-controlled clinical trials in MDD patients who had an inadequate response to other antidepressants. • If approved, Caplyta could become a first-choice add-on therapy for MDD, addressing a significant unmet need as over half of patients do not respond adequately to antidepressants alone.

Pharma Giants Report Q3 Earnings: Merck, Pfizer, AbbVie, and Novartis Lead with Key Drug Updates

• Merck's Keytruda sales surged 17% due to strong uptake in earlier-stage indications, while a new Phase III trial for a personalized mRNA cancer vaccine in NSCLC was initiated. • Pfizer's Q3 revenues increased by 32%, driven by non-COVID products and Seagen acquisitions, leading to raised 2024 earnings and revenue expectations. • AbbVie's Rinvoq and Skyrizi sales rose significantly due to label expansions, and the company is set to acquire Aliada for $1.4 billion to bolster its neuroscience pipeline. • Novartis' Scemblix received FDA approval for first-line Ph+ CML-CP, potentially quadrupling the eligible patient population, and the company raised its 2024 financial outlook.

AbbVie and Gedeon Richter Expand Collaboration to Tackle Neuropsychiatric Disorders

• AbbVie and Gedeon Richter have entered a new agreement to discover and develop novel targets for neuropsychiatric conditions, building on nearly two decades of partnership. • Richter will receive an upfront payment of $25 million and is eligible for future milestone payments and royalties, while AbbVie gains commercialization rights outside specific European markets. • The collaboration aims to address the significant unmet needs in neuropsychiatric disorders, which affect over 20% of adults in the United States. • The partnership highlights the ongoing efforts to innovate in CNS therapies, leveraging Richter's discovery platform and AbbVie's global reach.

FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors

• The FDA has approved Cobenfy (xanomeline and trospium chloride) as the first new class of drug for schizophrenia in over 30 years, offering a novel approach to treatment. • Cobenfy targets muscarinic receptors, unlike traditional antipsychotics that focus on dopamine, potentially reducing side effects like weight gain and movement disorders. • Clinical trials demonstrated Cobenfy significantly reduced schizophrenia symptoms compared to placebo, marking a transformative moment in managing this challenging condition. • Expected to launch in late October, Cobenfy offers a new option for adults with schizophrenia, with ongoing studies exploring its potential in Alzheimer's psychosis and other conditions.

AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates

• AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders. • The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. • Pfizer halted Phase III development of its twice-daily obesity drug, danuglipron, due to significant gastrointestinal side effects observed in Phase II trials. • Biogen and Eisai received full FDA approval for Leqembi, an Alzheimer's disease drug shown to slow cognitive decline, expanding Medicare coverage.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy